Antengene Corporation Limited | September 19, 2022
Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101.
At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide.
Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug.
Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths.
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S.
"We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world."
Dr. Bo Shan, Antengene's Chief Scientific Officer
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.
CareView Communications, Inc. | July 27, 2022
CareView Communications, Inc. an information technology provider to the healthcare industry, announced its recent partnership with HealthCare Support an Ingenovis Health company, and a national healthcare staffing platform providing a full range of customized hiring solutions across the United States.
“This partnership will allow us to provide a comprehensive, fully-managed patient safety and virtual care solution for healthcare facilities currently experiencing staffing shortages. CareView is excited to pair our CareView Patient Safety System® with HSS’s staffing expertise to monitor patients remotely and provide much-needed staffing services. We look forward to collaborating with HSS in sharing our vision for patient safety and virtual care. With the present shortage of hospital personnel and the availability of adding additional staff being in short supply, we are hopeful that the marketplace will embrace a new form of virtual employees.”
Steve Johnson, CareView’s CEO
CareView Patient Safety System enabled virtual nursing workflows for admissions and discharges can help reduce labor costs, improve efficiency, decrease staff burden and burnout, and enhance patient engagement.
The CareView Patient Safety System, including its patented Virtual Bed Rails® and Virtual Chair Rails®, uses predictive technology to differentiate between normal patient movements and behaviors of an at-risk patient. This results in fewer false alarms, quicker staff interventions, and a significant reduction in patient falls.
Chris Abel, President of HealthCare Support, says, “This is a pivotal time for the healthcare industry. Our relationship with CareView creates new opportunities for healthcare providers to address their staffing needs with technology, talent, and proven expertise. With our shared focus and commitment to providing much-needed staffing solutions across the industry, we expect to obtain great results for CareView and its customers.”
About CareView Communications, Inc.
As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next generation solutions that lower operational costs and foster a culture of safety among patient, staff and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.
About HealthCare Support
HealthCare Support, an Ingenovis Health company, is a national recruitment firm providing clinical and non-clinical staffing solutions to top healthcare organizations. By aligning the skills, values, and goals of healthcare professionals to the clients that serve their communities, HealthCare Support provides full cycle support to both clients and talent. Founded in 2003, HealthCare Support was named in 2020 as the 8th Largest Allied Healthcare Staffing Firm in the U.S. by Staffing Industry Analysts.
About Ingenovis Health
Ingenovis Health is an ingenious new force in healthcare combining the power of industry-leading staffing firms and enhanced technology to advance delivery of critical healthcare clinicians to systems nationwide. Brands in the portfolio currently include trustaff, Fastaff Travel Nursing, U.S. Nursing Corporation, CardioSolution, Vista Staffing Solutions and HealthCare Support.
Walmart and Memomi | June 30, 2022
Walmart and Memomi, an augmented reality optical tech companyannounced they have entered into an agreement for Walmart to acquire Memomi. This reinforces Walmart’s commitment to frictionless and omnichannel optical care.
Since 2019, Memomi has enabled digital measurements for all Walmart and Sam’s Optical customers, across more than 2,800 Walmart Vision Centers and 550 Sam’s Clubs, and also powers the Optical eCommerce experience on SamsClub.com. Acquiring Memomi, an AR company, is the next step in Walmart’s journey of offering personalized, affordable access to optical care. This acquisition furthers Walmart Health & Wellness’ strategy to deliver integrated, omnichannel healthcare, leveraging data and technology to improve engagement, health equity and outcomes.
“Customers are looking for access to care digitally, in their homes, and purchasing eyeglasses is no different. This acquisition supports our Health & Wellness mission to provide accessible care to the communities we serve.”
David Reitnauer, Vice President, Specialty Services, Walmart Health & Wellness
Memomi is a leading provider of technology to enhance virtual optical try-on experiences, helping customers virtually “try on” eyewear in real-time for a seamless, easy and fun omnichannel experience.
“Walmart’s ability to roll out our virtual try-on and contact-free digital measurements service in a short period of time shows how committed Walmart is to its customers’ need for digital care in-stores and at home,” said Ofer Saban, Chief Technology Officer, Memomi.
The acquisition is expected to close in the coming weeks, and Memomi employees will join the Walmart Global Tech organization.
“We’re excited to welcome the Memomi team to Walmart and add their capabilities to our leading virtual reality technology that is transforming the retail experience for our customers and members,” said Cheryl Ainoa, Senior Vice President, New Businesses & Emerging Tech, Walmart Global Tech.
“We are looking forward to joining Walmart and offering our innovations and user experiences to such a large scale both in-store and online,” said Salvador Nissi Vilcovsky, CEO, Memomi.
Walmart Inc. helps people around the world save money and live better - anytime and anywhere - in retail stores, online, and through their mobile devices. Each week, approximately 220 million customers and members visit approximately 10,500 stores and clubs under 48 banners in 24 countries and eCommerce websites. With fiscal year 2021 revenue of $559 billion, Walmart employs over 2.2 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity.
Memomi Labs Inc is a leading provider of cutting-edge technology to enhance virtual try-on user experiences through artificial intelligence, deep learning and augmented reality. Memomi helps customers virtually “try on” eyewear in real-time for a seamless, easy and fun omnichannel experience. In addition to the try-on experience, Memomi technology has created an accurate, easy measurement experience in-store once glasses are selected, leading to time savings for the customer and cost savings for the store. Memomi was founded in 2014 by Salvador Nissi Vilcovsky and Ofer Saban, experts in conceptualized solutions and interactive design.
Firmament and Panacea Healthcare Solutions | August 24, 2022
Firmament, a leading provider of structured equity capital solutions to small- and medium-sized enterprises, announced a growth capital investment in Panacea Healthcare Solutions ("Panacea"). Panacea provides strategic pricing, price transparency, chargemaster, compliance, and revenue integrity software and consulting services to healthcare companies across the full continuum of care. Firmament's investment will fuel innovation and expand Panacea's product suite through the acquisition of Holliday & Associates and First Healthcare Compliance. The combined company will be a leading provider of healthcare revenue integrity and compliance software and services to over 600 hospitals, health systems, physician practices, and accountable care organizations across the United States.
The executive management teams of Panacea, Holiday & Associates, and First Healthcare Compliance will remain in place, together with the majority of their former shareholders. Panacea CEO Frederick Stodolak will continue to serve as Chief Executive Officer of the combined platform and will expand his role to become an active Chairman of the Board.
Stodolak stated, "We are proud to partner with Firmament and are excited for our future growth and continued product innovation. With the acquisition of Holliday & Associates, we are excited that our customers will benefit from access to a comprehensive suite of chargemaster software tools from a single vendor. Furthermore, we look forward to expanding First Healthcare Compliance's popular learning platform to leverage Panacea's expertise in inpatient, outpatient, and physician coding and compliance."
"We have been partners with Panacea for many years and are thrilled to formally combine our two companies. With this step, our clients will benefit greatly as we integrate to become one of the industry's most comprehensive providers of revenue integrity software solutions."
Rosemary Holliday, Managing Partner at Holliday & Associates
"First Healthcare Compliance clients will benefit from the wide array of coding compliance and revenue integrity software solutions that Panacea offers," Julie Sheppard, President of First Healthcare Compliance, commented. "Our team looks forward to continuing to support our amazing clientele through expanded product offerings and continued investments into our compliance platform."
Green Campbell, Vice President at Firmament stated, "Healthcare providers today are overburdened by complex coding, pricing, and compliance rules. Panacea's price transparency, strategic pricing, coding, and compliance solutions sit at the forefront of the most relevant regulations impacting the healthcare industry today. We are proud to partner with the teams at Panacea, Holiday & Associates, and First Healthcare Compliance to support their continued growth and investments in cutting edge software and tech-enabled services."
About Panacea Healthcare Solutions
Panacea provides software and tech-enabled services that help healthcare organizations improve their revenue integrity, coding, and compliance with front-line expertise in mid-revenue cycle management. In an era where 95% of provider revenue is driven by accurate coding and defensible yet optimal pricing, clients trust Panacea to deliver unparalleled value in strategic pricing, price transparency, chargemaster, compliance, and revenue integrity solutions.
Firmament provides structured equity capital solutions to small- and medium-sized enterprises. Firmament is a value-added partner to entrepreneurs, management teams and business owners and curates solutions by deploying versatile capital in a user-friendly way. Firmament concentrates on software and services businesses with significant scaling potential in the healthcare, logistics, wellness and environmental sectors. With offices across the United States and in the United Kingdom, Firmament is focused on turning small business into big business.